Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.03

-1.8%

3:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (227)	6/16/1999 9:18:00 PM
From: Pseudo Biologist	Read Replies (2) of 52153

Re <<Celltech's "The anti-TNF collaboration with Bayer that went thud was a Chiron MAb, I believe. That may help as you start down your mucky path, as the project is probably still alive (on paper, if not in reality)." >> Here is the "paper life" celltech.co.uk Why couldn't this be another Embrel or Remicade? Naively, one can even see some advantages in Celltech's version (humanized vs. chimeric, IgG4 vs. IgG1 - meaning less likely to kill cells with TNF on the surface, etc). Or is there something about this particular antibody you don't like? Their myeloid leukemia project, partnered with AHP, is scheduled to have a BLA filed in the near future. Yes, Mike your characterization of this company as Centocor et al-like is right on as far as I can tell. Here is the table with all the clinical projects: celltech.co.uk (seems a bit out of date) PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next